I think June could be a good time to look for quality ASX 200 growth shares.
The five shares in this article all have strong long-term growth potential in my view.
They are not risk-free, and some trade on high expectations, but I think each could be worth buying next month. Here's why I like them.
Image source: Getty Images
Megaport Ltd (ASX: MP1)
Megaport is one ASX 200 growth share I would buy for exposure to digital infrastructure.
The company has long provided network-as-a-service technology, helping businesses connect more flexibly to cloud providers, data centres, and digital services.
But the story has become more interesting since its acquisition of Latitude.sh, which added compute and storage capabilities.
Since completion, Megaport has announced several large contracts through Latitude.sh across GPU, CPU, network, and storage services. That is one reason investors have become more bullish.
There is still execution risk, and the business needs to keep proving the opportunity. But if demand for AI, cloud, and data-heavy workloads keeps growing, I think Megaport could become a much more valuable platform.
Aristocrat Leisure Ltd (ASX: ALL)
Aristocrat Leisure is another ASX 200 growth share I rate highly.
The company is best known for gaming machines, but it has also built a meaningful digital gaming business. That gives it exposure to both land-based gaming and mobile entertainment.
What I like about Aristocrat is its product development strength. In gaming, great content can travel across markets and keep generating revenue for a long time.
The company also has financial strength, which gives it room to invest, acquire, and return capital when appropriate.
There are regulatory and consumer risks with this business, so it will not suit every investor. But as a global gaming technology company, I think Aristocrat remains one of the higher-quality growth options on the ASX.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is the kind of growth share that doesn't get the headlines it deserves.
The company provides enterprise software to governments, universities, councils, and large organisations. These customers need reliable systems for finance, payroll, asset management, student administration, and other important operations.
That makes the software sticky.
I like the recurring revenue, the long customer relationships, and the company's record of steady execution. The UK opportunity also gives TechnologyOne another growth lever if it can keep building momentum there.
The valuation can be demanding, but quality software businesses often are.
REA Group Ltd (ASX: REA)
REA Group is one of the strongest platform businesses on the ASX.
Its realestate.com.au platform benefits from a powerful network effect. Buyers and renters search where the listings are, while agents and sellers want to advertise where the audience is.
That loop gives the business a strong position in Australian property.
I also think REA has plenty of ways to grow beyond basic listings. Premium products, data, agent tools, property insights, and finance leads can all add value over time.
The housing market can be uneven, but I think REA's competitive position remains very hard to replicate.
Sigma Healthcare Ltd (ASX: SIG)
A final ASX 200 growth share I would buy next month is Sigma Healthcare.
I think it has become a much more attractive investment opportunity since merging with Chemist Warehouse.
The combined business has exposure to pharmacy retail, healthcare distribution, wellness products, and repeat-purchase consumer health needs.
I like that mix. Healthcare retail can be more resilient than many discretionary categories, while Chemist Warehouse gives the group a powerful brand and a large store network.
If management can execute well, I think Sigma could become a much larger and more valuable healthcare retail business over time.
Foolish takeaway
I think these five ASX 200 growth shares offer a lot for investors to like heading into June.
They are exposed to different areas of the market, from digital infrastructure and software to property, gaming, and healthcare retail. That gives the list a broader feel than simply backing one growth theme.
What stands out to me is the quality of the opportunities. Each business has a clear path to becoming more valuable over time if management keeps executing well. For patient investors, I think that makes them worth considering next month and well beyond it.
